Overall, the immunohistochemical study showed that invasive breast cancer cases were ER positive in 64 patients (54.7%), PR positive in 48 patients (41%), and HER2 positive in 18 patients (15.4%). This evidence concerns the gene PGR and invasive breast carcinoma.